Thermo Fisher Scientific Inc (TMO) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.
Total Revenue Chart for Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc (TMO) revenue for FY2025 was USD 44.6B, a 3.9% change from FY2024. Thermo Fisher Scientific Inc's revenue grew from USD 265.7M in 1985 to USD 44.6B in 2025 (16669.3% over 40 years). Earnings per share grew from USD 0.38 in 2000 to USD 17.78 in 2025 (4604.2%). Revenue compound annual growth rate: 5-year CAGR of 6.7%, 10-year CAGR of 10.1%, 20-year CAGR of 15.2%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $214.46B
- Implied Share Price
- $580.02
- Enterprise Value
- $247.30B
- Revenue (TTM)
- $46.34B
- EBITDA
- $11.74B
- Profit Margin
- 15.04%
- Trailing P/E
- 31.05
- Forward P/E
- 22.47
- Price/Book (MRQ)
- 3.96
- Price/Sales (TTM)
- 4.63
- EV/EBITDA
- 20.53
- EV/Revenue
- 5.34
- Dividend Yield
- 0.31%
- Book Value
- $139.75
- Free Cash Flow (FY2025)
- $6.29B
- Free Cash Flow Yield
- 2.93%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.